ULB research| Personal data | Research themes | Ongoing teaching | Publications |
ROOMAN Marianne
Units
IB² Interuniversity Institute of Bioinformatics in Brussels
IB² is a collaborative bioinformatics research environment in Brussels. The goal of the IB² is to bring together research groups in and around Brussels requiring bioinformatics and computational biology expertise. IB² is an interuniversity, cross-faculty (Medicine, Sciences, and Applied Sciences) collaborative space located on the La Plaine campus of the Université Libre de Bruxelles.
Theoretical Physics : Fundamental Interactions
Our research is at the interface between fundamental interactions, including gravity, and cosmology. We use experiments and observations from colliders, telescopes, underground detectors, etc, to uncover the laws of nature beyond those encompassed within the Standard Model of particle physics. The topics we are concerned with include the nature and origin of dark matter and dark energy, the physics of neutrinos, the origin of the baryon asymmetry of the universe and its relation to CP violation and, last but not least, the mechanism at the origin of the mass of elementary particles (the Brout-Englert-Higgs mechanism).
Computational Biology & Bioinformatics
Person in charge of the Unit : Oui
Projetcs
The control of physicochemical and biological properties of proteins is a major challenge in all biotechnology sectors. Indeed, proteins are increasingly used as catalysts for their high specificity and performance in the development of environmentally friendly bioprocesses. In addition, therapeutic proteins, monoclonal antibodies and protein vaccines are of key importance for the biopharmaceutical field. With the rise of structural bioinformatics, it becomes feasible to rationally design optimized biological molecules. Even though the in silico approaches cannot lead to ideal success rates given the extreme complexity of biological systems, they make it nevertheless possible to propose a limited number of candidate molecules to be validated experimentally. This drastically reduces the number of experiments, which has a series of positive effects such as reduced costs, decrease and better targeting of animal experimentation, and the advent of a general technology that is more compatible with sustainable development.
The control of physicochemical and biological properties of proteins is a major challenge in all biotechnology sectors. Indeed, proteins are increasingly used as catalysts for their high specificity and performance in the development of environmentally friendly bioprocesses. In addition, therapeutic proteins, monoclonal antibodies and protein vaccines are of key importance for the biopharmaceutical field. With the rise of structural bioinformatics, it becomes feasible to rationally design optimized biological molecules. Even though the in silico approaches cannot lead to ideal success rates given the extreme complexity of biological systems, they make it nevertheless possible to propose a limited number of candidate molecules to be validated experimentally. This drastically reduces the number of experiments, which has a series of positive effects such as reduced costs, decrease and better targeting of animal experimentation, and the advent of a general technology that is more compatible with sustainable development.
